|
ATCC
thp 1 cells ![]() Thp 1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/thp 1 cells/product/ATCC Average 99 stars, based on 1 article reviews
thp 1 cells - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
InvivoGen
thp 1 dual cells ![]() Thp 1 Dual Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/thp 1 dual cells/product/InvivoGen Average 98 stars, based on 1 article reviews
thp 1 dual cells - by Bioz Stars,
2026-02
98/100 stars
|
Buy from Supplier |
|
ATCC
monocytic leukaemia cell line thp ![]() Monocytic Leukaemia Cell Line Thp, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/monocytic leukaemia cell line thp/product/ATCC Average 99 stars, based on 1 article reviews
monocytic leukaemia cell line thp - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
monocytic leukaemia cell line thp 1 ![]() Monocytic Leukaemia Cell Line Thp 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/monocytic leukaemia cell line thp 1/product/ATCC Average 99 stars, based on 1 article reviews
monocytic leukaemia cell line thp 1 - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
cell lines thp 1 ![]() Cell Lines Thp 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cell lines thp 1/product/ATCC Average 99 stars, based on 1 article reviews
cell lines thp 1 - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
human monocytic cell line thp 1 ![]() Human Monocytic Cell Line Thp 1, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human monocytic cell line thp 1/product/ATCC Average 99 stars, based on 1 article reviews
human monocytic cell line thp 1 - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
human leukemia monocytic thp 1 cells ![]() Human Leukemia Monocytic Thp 1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human leukemia monocytic thp 1 cells/product/ATCC Average 99 stars, based on 1 article reviews
human leukemia monocytic thp 1 cells - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
thp1 cell line ![]() Thp1 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/thp1 cell line/product/ATCC Average 99 stars, based on 1 article reviews
thp1 cell line - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
|
ATCC
human monocyte cells ![]() Human Monocyte Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human monocyte cells/product/ATCC Average 99 stars, based on 1 article reviews
human monocyte cells - by Bioz Stars,
2026-02
99/100 stars
|
Buy from Supplier |
Journal: STAR Protocols
Article Title: Protocol to study the role of endogenously produced itaconate using CRISPR-Cas9 technology in THP-1 cells
doi: 10.1016/j.xpro.2025.104304
Figure Lengend Snippet: Validation of IRG1 KO by Immunoblot Analysis WT and IRG1 KO THP-1 cells were differentiated with PMA (100 nM, 72 hr) and subsequently simulated with vehicle control or LPS (200 ng/mL) and IFNγ (200 ng/mL) for 6 and 24 hr. The abundance of IRG1 is demonstrated by immunoblot analysis with β-Actin serving as a loading control.
Article Snippet:
Techniques: Biomarker Discovery, Western Blot, Control
Journal: STAR Protocols
Article Title: Protocol to study the role of endogenously produced itaconate using CRISPR-Cas9 technology in THP-1 cells
doi: 10.1016/j.xpro.2025.104304
Figure Lengend Snippet: Endogenously produced itaconate is required to produce IFNβ protein WT and IRG1 KO THP-1 cells were differentiated with PMA (100 nM, 72 hr) and subsequently simulated with vehicle control or LPS (200 ng/mL) and IFNγ (200 ng/mL) for 6 and 24 hr ( n = 3 biological replicates for each timepoint). Data are represented as mean ± SD.
Article Snippet:
Techniques: Produced, Control
Journal: STAR Protocols
Article Title: Protocol to study the role of endogenously produced itaconate using CRISPR-Cas9 technology in THP-1 cells
doi: 10.1016/j.xpro.2025.104304
Figure Lengend Snippet: Representative chromatograms for itaconate, citraconate, mesaconate, and the 13 C 5 -itaconic acid internal standard (A) neat standards for itaconate and its isomers citraconate and mesaconate. Shown are the 129.000/85.100 m/z MRM channel for itaconate, citraconate, and mesaconate (blue; 50 ng/mL each) and the 133.926/89.100 m/z MRM channel for 13 C 5 -itaconic acid (pink; 100 ng/mL). Expected retention times for itaconate/ 13 C 5 -itaconate, citraconate, and mesaconate are 2.83 min, 2.17 min, and 2.73 min, respectively. (B) cell lysate from a wild type THP-1 sample stimulated for 24 hours with LPS and IFNγ (200 ng/mL each). (C) supernatant from a wild type THP-1 culture stimulated for 24 hours with LPS and IFNγ (200 ng/mL each).
Article Snippet:
Techniques:
Journal: STAR Protocols
Article Title: Protocol to study the role of endogenously produced itaconate using CRISPR-Cas9 technology in THP-1 cells
doi: 10.1016/j.xpro.2025.104304
Figure Lengend Snippet: Itaconate levels quantified by LC-MS (A) Itaconate in culture supernatant and (B) cell lysate from PMA-differentiated WT and IRG1 KO THP-1 cultures stimulated with LPS and IFNγ (200 ng/mL each) ( n = 8 biological replicates for each timepoint). Data are represented as mean ± SD.
Article Snippet:
Techniques: Liquid Chromatography with Mass Spectroscopy
Journal: eLife
Article Title: Suppression of interferon signaling via small-molecule modulation of TFAM
doi: 10.7554/eLife.108742
Figure Lengend Snippet: ( A ) Flowchart of the CXCL-10 experiment. ( B ) Compounds 2 , 3 , and 15 repressed ISG signaling in CXCL-10 production. THP-1 cells were pre-treated with individual compounds 48 h prior to 100 ng/mL TNFa stimulation for 48 h. CXCL-10 levels were measured. ( C ) Flowchart of the ISRE experiment. ( D ) Compounds 2 , 3 , and 15 repressed ISG signaling in IRF3 production. THP-1-Dual cells were pre-treated with individual compounds 24 h prior to 100 ng/mL TNFa stimulation for 48 h. The inhibition of type I IFN response was monitored via ISRE reporter activation. Figures are representatives of at least two independent experiments. Graph shows one representative experiment of two independent experiments. Error bars represent ± SD from n=3 biological replicates. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Source data for this figure are available in (raw data and analysis). Figure 2—source data 1. Raw data and analysis results to generate the graphs shown in .
Article Snippet:
Techniques: Inhibition, Activation Assay
Journal: eLife
Article Title: Suppression of interferon signaling via small-molecule modulation of TFAM
doi: 10.7554/eLife.108742
Figure Lengend Snippet: ( A ) Chemical structures of hit compounds and related analogs. ( B ) TFAM modulators were profiled in the ISRE assay and display dose-dependent suppression of ISG signaling. THP-1-Dual cells were pre-treated with individual compounds 24 h prior to 100 ng/mL TNFa stimulation for 48 h. ISRE reporter activation was measured. Figures are representatives of at least two independent experiments. Graph shows one representative experiment of two independent experiments. Error bars represent ± SD from n=3 biological replicates. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Source data for this figure are available in (raw data and analysis). Figure 3—source data 1. Raw data and analysis results to generate the graphs shown in .
Article Snippet:
Techniques: Activation Assay
Journal: eLife
Article Title: Suppression of interferon signaling via small-molecule modulation of TFAM
doi: 10.7554/eLife.108742
Figure Lengend Snippet: ( A ) ISRE reporter activation of THP-1 dual cells stimulated with 100 ng/mL TNFa for 48 h. Compounds were added to the cells 5 min before the assay detection. Figures are representatives of at least two independent experiments. Graph shows one representative experiment of two independent experiments. Error bars represent ± SD from n=3 biological replicates. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Source data for this figure are available in (raw data and analysis).
Article Snippet:
Techniques: Activation Assay
Journal: eLife
Article Title: Suppression of interferon signaling via small-molecule modulation of TFAM
doi: 10.7554/eLife.108742
Figure Lengend Snippet: ( A ) Compounds 2 , 3 , and 15 do not repress cGAMP induced ISG signaling. THP-1-Dual cells were pre-treated with individual compounds 48 h prior to 10 ug/mL cGAMP stimulation for 24 h. ISRE reporter activation was measured. ( B ) Compounds 2 , 3 , and 11 impart a dose-dependent increase in TFAM protein levels. Immunoblot analysis of TFAM from T47D cells treated with indicated compounds for 5 days. ( C ) Compounds exhibit minimal impact on TFAM mRNA levels. ( D ) Downregulation of TFAM attenuates the function of compounds 2 and 3 in repression of ISG signaling. THP-1-Dual cells were treated with individual compounds 24 h after siRNA transfection. After incubation for 24 h, THP-1-Dual cells were stimulated with 100 ng/mL TNFa for another 48 h. ISRE reporter activation was measured and normalized to protein concentration. ( E ) Compound 3 inhibits mtDNA cytosolic leakage. THP-1 cells were pre-treated with individual compounds 72 h prior to 100 ng/mL TNFa stimulation for 48 h. Cytosolic mtDNA was extracted and quantified using a qPCR assay. Figures are representatives of at least two independent experiments. Graph shows one representative experiment of two independent experiments. Error bars represent ± SD from n=3 biological replicates. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Source data for this figure are available in (original uncropped blots) and (annotated uncropped blots), and (raw data and analysis). Figure 4—source data 1. Original uncropped western blot images for . Figure 4—source data 2. Annotated uncropped western blot images for , with treatment conditions and protein identities indicated. Figure 4—source data 3. Raw data and analysis results to generate the graphs shown in .
Article Snippet:
Techniques: Activation Assay, Western Blot, Transfection, Incubation, Protein Concentration
Journal: Journal of Cellular and Molecular Medicine
Article Title: Exosomal HMGB1 Orchestrates NSCLC Progression and Immunosuppressive Macrophage Polarisation Through the TLR4 / NF ‐ κB / IL ‐6/ STAT3 Signalling Cascade
doi: 10.1111/jcmm.71050
Figure Lengend Snippet: Targeting HMGB1 signalling improves therapeutic outcomes in NSCLC. (A) Correlation analysis between immune infiltration scores and HMGB1 expression in 491 LUAD and 500 LUSC patients from the TCGA database. (B) Correlation between HMGB1 expression and the distribution of various immune cell subsets in LUAD and LUSC patients. (C, D) THP‐1–derived M0 macrophages were treated with PBS, HMGB1 (10 or 100 ng) or exosomes derived from vector or HMGB1 OE cells (cell‐to‐exosome ratio = 1:10). M1 macrophage markers (CD86, CD80, iNOS) and M2 markers (CD206, IL‐10, Arg1) were quantified by PCR. (E) Lewis tumour‐bearing mice were treated with PBS, HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse, twice per week), anti‐PD‐1 antibody (RMP1‐14, 200 μg per mouse, twice per week) or combination therapy ( n = 5 per group). Tumour volumes and apoptosis levels in tumour tissues (day 25) were assessed. (F) PC9 cells were treated with PBS or exosomes from HMGB1 OE cells (cell‐to‐exosome ratio = 1:10), followed by Osimertinib (50 nM, 48 h), and apoptosis was measured. (G) A549 and PC9 cells were similarly treated with PBS or HMGB1 OE‐derived exosomes, followed by Cisplatin (5 μM, 48 h), and apoptosis was analysed. (H) A549 and PC9 cells were similarly treated with paclitaxel (10 μM, 48 h) under the same conditions, and cell apoptosis was determined. (I) A549‐bearing mice were treated with HMGB1 OE‐derived exosomes (1 × 10 10 exosomes per mouse), followed by PBS, paclitaxel (PTX, 10 mg/kg, twice per week), STAT3 inhibitor (5 mg/kg, twice per week) or combination therapy. (J) Schematic diagram illustrating the proposed mechanism: HMGB1 upregulates TLR4, thereby activating the NF‐κB–IL‐6 axis and stimulating JAK2/STAT3 signalling to promote tumour progression. Concurrently, HMGB1 facilitates M2 macrophage polarisation.
Article Snippet: Human NSCLC cell lines (A549, PC9), human embryonic kidney cells (HEK293T) and the human
Techniques: Expressing, Derivative Assay, Plasmid Preparation
Journal: Clinical and Translational Medicine
Article Title: Integrative single‐cell analysis uncovers distinct tumour microenvironment ecotypes and immune evasion across skin cancers
doi: 10.1002/ctm2.70611
Figure Lengend Snippet: Ecotypes and cell‒cell communication networks in skin tumour microenvironment. (A) Heatmap showing the five ecotypes of skin tumours, which were inferred based on tumour microenvironment cell compositions. Bar plot showing the distribution of various cell lineages in each sample. (B) Pie charts showing ecotype distribution across tumour types and stages. (C) Pie charts showing tumour‐stage compositions across ecotypes. (D) Bar plots of enriched ligand‒receptor interactions for ecotype 1 and ecotype 4. (E) Cell‒cell communication networks showing MHC‐I signalling interactions in ecotype 1 and ecotype 4 (top) and SPP1 signalling interactions in ecotype 1 and ecotype 4 (bottom). Edge thickness indicates interaction strength, and colours represent different cell lineages. (F) Violin plots showing the expression of HLA‐A (top) and SPP1 (bottom) with associated partner genes (CD8A, CD44) across cell types and ecotypes. (G) qRT‐PCR showing Spp1 expression in RAW264.7 macrophages cultured with conditioned medium from B16 melanoma cells. (H) Western blot showing Spp1 protein levels in tumour‐associated macrophages (TAMs) after B16‐conditioned medium treatment, with corresponding quantification. (I) qRT‐PCR showing M2 polarisation markers expression in RAW264.7 macrophages after B16‐conditioned medium treatment. (J) qRT‐PCR showing SPP1 mRNA expression in THP‐1 macrophages transduced with control short hairpin RNA (shRNA) (negative control shRNA [shNC]) or two independent SPP1 ‐targeting shRNAs (shSPP1‐1# and shSPP1‐2#) (K) Western blot showing SPP1 protein levels in shNC, sh SPP1 ‐1# and sh SPP1 ‐2# THP‐1 cells. (L) M2 polarisation markers ( ARG‐1 , MRC1 and CD163) were measured in shNC or sh SPP1 THP‐1 macrophages cultured with SK‐MEL‐28‐conditioned medium. (M) qRT‐PCR showing SPP1 mRNA expression in THP‐1 macrophages transduced with empty vector (EV) or SPP1 overexpression construct (SPP1‐OE). (N) Western blot showing SPP1 protein levels in EV and SPP1 ‐OE THP‐1 cells. (O) M2 polarisation markers ( ARG‐1 , MRC1 and CD163 ) were measured in EV/ SPP1 ‐OE THP‐1 macrophages cultured with SK‐MEL‐28‐conditioned medium. Data are presented as mean ± SD. n = 3 independent repeats. Unpaired, two‐tailed t ‐test; * p < .05, ** p < .01, *** p < .001, **** p < .0001.
Article Snippet: The
Techniques: Expressing, Quantitative RT-PCR, Cell Culture, Western Blot, Transduction, Control, shRNA, Negative Control, Plasmid Preparation, Over Expression, Construct, Two Tailed Test
Journal: The Journal of Experimental Medicine
Article Title: Tet2 deficiency–induced expansion of monocyte-derived macrophages promotes liver fibrosis
doi: 10.1084/jem.20251114
Figure Lengend Snippet: Tet2 deficiency enhances Ccl2 and Ccl8 mRNA stability by modifying 5hmC-dependent RNA – protein interactions. (A and B) Ccl2 (A) and Ccl8 (B) mRNA decay in Tet2 +/+ and Tet2 −/− MDMs ( n = 6 for each group). (C) Tet2 -mediated oxidation of Ccl2 and Ccl8 mRNA 5mC disrupts its binding with Ybx1, Elavl1, and Zfp36. Pull-down assay was performed by incubating C, 5mC, and 5hmC oligos of Ccl2 and Ccl8 mRNA with cell lysate from THP1-derived pMDMs ( n = 3 for each group). (D) Effect of Tet2 deficiency on the binding enrichment of Ybx1, Elavl1, and Zfp36 at 3′UTR of Ccl2 and Ccl8 mRNA. Tet2-binding sites were mapped in the mRNA of Ccl2 and Ccl8 by qPCR of Ybx1, Elavl1, and Zfp36 RIP product in THP1-derived pMDMs ( n = 3 for each group). (E and F) Effect of enzymatic inactivation of Tet2 via catalytic domain mutation on stabilization of Ccl2 (F) and Ccl8 (G) transcripts ( n = 4 for each group). Data are the accumulative results from at least two independent experiments (A, B, D, E, and F) or are representative of at least two independent experiments with similar results (C and D). All data are shown as mean ± SD and were analyzed by two-tailed, unpaired Student’s t test (A, B, and D–F). ***P < 0.001; **P < 0.01; *P < 0.05; P > 0.05 not significant (ns). Source data are available for this figure: .
Article Snippet:
Techniques: Binding Assay, Pull Down Assay, Derivative Assay, Mutagenesis, Two Tailed Test